Please select a day:
02.10.2013
03.10.2013
04.10.2013
05.10.2013
Search

Personal programme
Please enter your email address here in order to bring up your personal programme






Search result



Search Result: Abstracts

Thursday, October 03, 2013

15:45 - 17:00 Poster Session : Treatment of specific symptoms
Alemtuzumab improves expanded disability status scale (EDSS) via effects on functional systems: CARE-MS II P 649
V. Brinar, D.L. Arnold, J. Cohen, A.J. Coles, E.J. Fox, H.-P. Hartung, E. Havrdova, K. Selmaj, H. Weiner, J. Palmer, D.H. Margolin, M.A. Panzara, D.A.S. Compston (Zagreb, HR; Montreal, CA; Cleveland, US; Cambridge, GB; Round Rock, US; Düsseldorf, DE; Prague, CZ; Lodz, PL; Boston, Cambridge, US)
15:45 - 17:00 Poster Session : Treatment of progressive MS
Phase 1 trial monitoring response to alemtuzumab (ALE) in naive and ALE-experienced subjects with refractory multiple sclerosis (MS) P 616
S.F. Hunter, H.M. Hunter, D. Kantor (Franklin, Golden Valley, Ponte Vedra, US)
15:45 - 17:00 Poster Session : Risk management for disease modifying treatments
Detection, incidence and management of glomerulonephritis in the alemtuzumab clinical development programme P 597
D. Wynn, D.L. Arnold, J.A. Cohen, A.J. Coles, E.J. Fox, H.-P.. Hartung, E. Havrdova, K.W. Selmaj, H.L. Weiner, J. Palmer, D.H. Margolin, P. Oyuela, M.A. Panzara, DAS Compston (Northbrook, US; Montreal, CA; Cleveland, US; Cambridge, GB; Round Rock, US; Düsseldorf, DE; Prague, CZ; Lodz, PL; Boston, Cambridge, US)
15:45 - 17:00 Poster Session : Immunomodulation/Immunosuppression
Anti-CD52 therapy induces significant changes in T and B cell subset frequency and cytokine expression by B cells in multiple sclerosis patients P 542
D. Mielcarz, A. Bergeron, J. DeLong, C. Sears, R. Grady, J. Channon, L. Kasper (Lebanon, US)
15:45 - 17:00 Poster Session : Immunomodulation/Immunosuppression
Immunogenicity of alemtuzumab does not impact safety and efficacy in relapsing remitting multiple sclerosis patients in the CARE-MS I study P 523
T. Ziemssen, D.L. Arnold, J.A. Cohen, A.J. Coles, E.J. Fox, H.-P. Hartung, E. Havrdova, K.W. Selmaj, H.L. Weiner, J. Palmer, D.H. Margolin, S. Richards, C. Sung, M.A. Panzara, D.A.S. Compston (Dresden, DE; Montreal, CA; Cleveland, US; Cambridge, GB; Round Rock, US; Düsseldorf, DE; Prague, CZ; Lodz, PL; Boston, Cambridge, US)
15:45 - 17:00 Poster Session : Others
Alemtuzumab as rescue therapy in a cohort of 15 aggressive multiple sclerosis patients previously treated by mitoxantrone: an observational study P 629
E. Le Page, V. Deburghgraeve, G. Edan (Rennes, FR)
15:45 - 17:00 Poster Session : Others
Which drugs are most effective for relapsing remitting multiple sclerosis? A network metaanalysis of disease modifying therapies P 628
E. Fogarty, S. Schmitz, C. Walsh, N. Tubridy, M. Barry (Dublin, IE)
15:45 - 17:00 Poster Session : Immunomodulation/Immunosuppression
Lymphocyte counts and efficacy outcomes after alemtuzumab in relapsing remitting multiple sclerosis patients: the CARE-MS studies P 515
P.S. Sorensen, D.L. Arnold, J.A. Cohen, E.J. Fox, H.-P. Hartung, E. Havrdova, K. Selmaj, H. Weiner, J. Palmer, D.H. Margolin, M.A. Panzara, D.A.S. Compston, A.J. Coles (Copenhagen, DK; Montreal, CA; Cleveland, Round Rock, US; Düsseldorf, DE; Prague, CZ; Lodz, PL; Boston, Cambridge, US; Cambridge, GB)
15:45 - 17:00 Poster Session : Risk management for disease modifying treatments
Infection risk with alemtuzumab in patients with relapsing remitting multiple sclerosis: pooled results from the CARE-MS I and CARE-MS II trials P 603
E. Havrdova, D.L. Arnold, J.A. Cohen, A.J. Coles, E.J. Fox, H.-P. Hartung, K. Selmaj, H.L. Weiner, J. Palmer, D.H. Margolin, P. Oyuela, M.A. Panzara, D.A.S. Compston (Prague, CZ; Montreal, CA; Cleveland, US; Cambridge, GB; Round Rock, US; Düsseldorf, DE; Lodz, PL; Boston, Cambridge, US)
15:45 - 17:00 Poster Session : Immunomodulation/Immunosuppression
Lymphocyte subset dynamics following alemtuzumab treatment in the CARE-MS II study P 531
L.H. Kasper, D.L. Arnold, J.A. Cohen, A.J. Coles, E.J. Fox, H.-P. Hartung, E. Havrdova, K.W. Selmaj, H.L. Weiner, J. Palmer, D.H. Margolin, M.A. Panzara, D.A.S. Compston (Lebanon, US; Montreal, CA; Cleveland, US; Cambridge, GB; Round Rock, US; Düsseldorf, DE; Prague, CZ; Lodz, PL; Boston, Cambridge, US)
15:45 - 17:30 Poster Session : Long-term treatment monitoring
Reduction of disability with alemtuzumab in relapsing remitting multiple sclerosis patients who participated in CARE-MS II: three year follow-up P 592
H.-P. Hartung, D.L. Arnold, J.A. Cohen, A.J. Coles, E.J. Fox, E. Havrdova, K.W. Selmaj, H.L. Weiner, J. Palmer, D.H. Margolin, M.A. Panzara, D.A.S. Compston (Dusseldorf, DE; Montreal, CA; Cleveland, US; Cambridge, GB; Round Rock, US; Prague, CZ; Lodz, PL; Boston, Cambridge, US)
17:25 - 17:45 Hot Topic 2 : Can immunomodulatory treatment change the natural history of MS? (Hall A)
Use of historical controls to compare treatment effects in MS 136
N. Koch-Henriksen (Copenhagen / Aarhus, DK)

Friday, October 04, 2013

10:45 - 11:05 Parallel Session 8 : Management of risk in MS therapy (Hall A)
Is risk stratification possible with the new treatments? 176
P.S. Sĝrensen (Copenhagen, DK)
14:20 - 14:40 Parallel Session 10 : Progressive MS (Hall A)
Therapeutic opportunities for progressive MS 196
F. Sellebjerg (Copenhagen, DK)
15:30 - 17:00 Poster Session : Late Breaking News
Preservation of lymphocyte migratory ability following anti-CD52 therapy P 1207
M.J. Turner, E. Havari, J. Dodge, C. Treleaven, L. Shihabuddin, B. Roberts, J. Kaplan, W.M. Siders (Framingham, US)
15:30 - 17:00 Poster Session : Long-term treatment monitoring
Adverse event profile of alemtuzumab in active relapsing remitting multiple sclerosis patients who participated in the CARE-MS studies: three-year follow-up P 1053
J. Lycke, D.L. Arnold, J.A. Cohen, A.J. Coles, E.J. Fox, H.-P. Hartung, E. Havrdova, K.W. Selmaj, H.L. Weiner, J. Palmer, D.H. Margolin, P. Oyuela, M.A. Panzara, D.A.S. Compston (Gothenburg, SE; Montreal, CA; Cleveland, US; Cambridge, GB; Round Rock, US; Düsseldorf, DE; Prague, CZ; Lodz, PL; Boston, Cambridge, US)
15:30 - 17:00 Poster Session : Late Breaking News
Differential lymphocyte reconstitution after treatment of relapsing-remitting multiple sclerosis with alemtuzumab is not linked to disease stability P 1198
O. Kousin-Ezewu, L. Azzopardi, O. Tuohy, R. Parker, A. Coles, J. Jones (Cambridge, GB)





show more results